House panel seeks tighter price and margin controls for non-scheduled medicines
A parliamentary committee has urged stronger monitoring of medicine MRPs, trade margins and fixed-dose combinations, flagging that non-scheduled drugs account for 82% of India’s pharma market by value and remain outside direct price controls.
What happened
National Pharmaceutical Pricing Authority (NPPA) · A parliamentary panel urged tighter price and trade-margin controls for non-scheduled medicines, citing weak
Key facts
- Non-scheduled medicines account for 82% of India's pharma market by value
- 4% of the non-scheduled market has weighted-average mark-ups above 100%
- 87% of the market has mark-ups up to 45%
- Annual MRP increases for non-scheduled medicines are capped at 10%
- The committee rejected government replies on 7 of 11 recommendations
Why this matters
Deal teams should reprice pharma-retail and consumer-health targets for regulatory margin compression, prioritizing assets with resilient volumes, differentiated brands and less dependence on discretionary pricing.
What to watch
- Department of Pharmaceuticals or NPPA consultation on non-scheduled drug MRPs, trade margins or expansion of the National List of Essential Medicines.
- Creation of a mandatory medicine price and margin reporting system for manufacturers, distributors or retailers.
- NPPA notices targeting specific high-consumption formulations, therapeutic classes or fixed-dose combinations.
- Any proposal to cap trade margins at the retailer or distributor level rather than only setting manufacturer price ceilings.
- Manufacturer announcements of price revisions, SKU discontinuations or changes in channel schemes for branded generics.
- Evidence of pharmacy chains increasing mix in OTC, wellness, diagnostics and private-label categories as prescription-drug margin pressure emerges.
- Audit exposure by molecule, therapy area and manufacturer to identify non-scheduled products with unusually high MRPs, retailer margins or distributor incentives.
- Reduce dependence on high-margin branded generics by expanding private-label OTC, diagnostics, wellness, devices and subscription-based chronic-care offerings.
- Renegotiate supplier terms toward fixed service fees, volume rebates and supply guarantees rather than MRP-linked trade margins that could attract regulatory scrutiny.
- Build pricing and margin traceability across procurement, distributor and store levels to support compliance with potential disclosure or audit rules.
- Prepare consumer-facing value messaging and lower-priced substitute recommendations, especially for chronic therapies where price comparisons can drive store switching.
- Monitor inventory levels in categories vulnerable to pre-regulation price increases, SKU withdrawals or manufacturer supply rationalization.